Creative Financial Designs’s BridgeBio Pharma BBIO Stock Holding History

Creative Financial Designs’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16	Closed	-$553	–	2029
2025 Q1	$553	Buy	+16	New	+$540	﹤0.01%	1899

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Creative Financial Designs's BBIO Position: Q2 2025 in Review

Creative Financial Designs sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 16 shares — an estimated $553 sold.

Creative Financial Designs first reported a position in BBIO in Q1 2025 and held it in 1 quarter. The position peaked at $553 in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Creative Financial Designs reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Creative Financial Designs sold 16 BridgeBio Pharma shares in Q2 2025, an estimated $553.
Creative Financial Designs first reported a position in BridgeBio Pharma in Q1 2025 and held it in 1 quarter.
Creative Financial Designs's BridgeBio Pharma position peaked at $553 in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Creative Financial Designs's 13F filing for Q2 2025, filed 4 Aug 2025.